Oklo (OKLO) Stock
Full research prompt
What is Oklo's (OKLO) share price, market cap and enterprise value as of mid-November 2026, and what is its latest cash and marketable securities balance after Q3 2026 results?
From Company Analysis: Oklo (OKLO) — Small Modular Nuclear Reactors for the AI Era
Oklo's most valuable asset is its fuel recycling thesis, which enables efficient reuse of nuclear fuel and positions it for the AI data center boom. The market has not yet priced in the full extent of this advantage over traditional reactors. This recycling mechanism underpins Oklo's edge in cost and scalability.
As of mid-November 2026 (around November 13–16), Oklo (NYSE: OKLO) shares traded in the low-to-mid $23 range amid volatility, with market cap near $4.5–4.7 billion and enterprise value significantly lower at around $2.1–2.2 billion due to a large net cash position. The latest reported liquidity after Q3 2026 (ended September 30) stood at $3.131 billion in cash, cash equivalents, and marketable debt securities.[1][2]
Share price on/around November 16, 2026, hovered near $23–24 intraday or at close, following a November 13 close of approximately $23.92. Multiple real-time quotes on November 16 showed prices such as $23.55, $23.29, $23.18, $23.23, and $23.05 during trading hours, with the prior close at $23.92. The stock had declined sharply from its 52-week high of ~$115.72 earlier in the year.[3][4][5]
Market capitalization stood at approximately $4.5–4.7 billion. This reflects roughly 195.29 million shares outstanding (or ~195.16–195.3 million as of late Q3/early November 2026) multiplied by the prevailing share price in the low-to-mid $23s. Specific figures from sources include $4.62B, $4.55B, $4.67B, and $4.54B.[1][6][7]
Enterprise value was reported around $2.1–2.2 billion (or in one case ~$3.1B), substantially below market cap due to Oklo’s large cash and securities holdings and minimal debt. GuruFocus listed EV at $2.10B and stockanalysis.com at $2.17B alongside a ~$4.67B market cap. This reflects a net cash position exceeding $2.5 billion.[2][6]
Post-Q3 2026 results (released November 6, 2026), the company reported $3.131 billion in cash, cash equivalents, and marketable debt securities as of September 30, 2026. This comprised ~$1.550 billion in cash and cash equivalents, ~$951.8 million in current marketable debt securities, ~$629 million in non-current marketable debt securities, and ~$81.9 million in restricted cash. Total assets reached ~$3.768 billion against low liabilities (~$120 million). The figure includes proceeds from at-the-market equity offerings (~$2.3 billion raised in the first three quarters). Guidance for full-year 2026 operating cash use remained $120–150 million.[8][9][10]
These figures are drawn from recent market data aggregators, financial sites, and summaries of Oklo’s SEC filings (primarily the Q3 2026 10-Q). Stock prices and valuations fluctuate intraday; the Q3 balance sheet represents the most recent detailed liquidity disclosure available as of November 16, 2026. Enterprise value calculations can vary slightly by methodology (e.g., inclusion of restricted cash or exact debt figures), but the gap versus market cap consistently highlights Oklo’s strong net cash position relative to its pre-revenue development stage.
Sources
- {uri: "https://longbridge.com/en/quote/OKLO.US", title: "1"}
- {uri: "https://www.gurufocus.com/stock/OKLO/report", title: "2"}
- {uri: "https://pro.stockalarm.io/quote/OKLO/metric/price", title: "3"}
- {uri: "https://www.coinbase.com/en-ca/stock/OKLO", title: "4"}
- {uri: "https://www.macroaxis.com/oklo-inc-stock-price-history", title: "5"}
- {uri: "https://stockanalysis.com/stocks/oklo/", title: "6"}
- {uri: "https://sectracker.app/en/OKLO", title: "7"}
- {uri: "https://www.stocktaper.com/earningsCallSummary/OKLO/2026/Q3", title: "8"}
- {uri: "https://quartr.com/companies/oklo-inc_15051", title: "9"}
- {uri: "https://www.minichart.com.sg/2026/11/06/oklo-q3-2026-41-7m-net-loss-3-13b-liquidity-as-pre-commercial-nuclear-firm-builds-cash/", title: "10"}
This AI-generated research is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Luminix is not a registered investment advisor. Always consult a qualified financial advisor before making investment decisions. Data may contain inaccuracies — verify independently before acting.